Rockwell Medical Inc
RMTI0.970USD
+0.014+1.46%
Market hours （ET）Quotes delayed by 15 min
33.23MMarket Cap
LossP/E TTM
More Details of Rockwell Medical Inc Company
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers around the world. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. It is the supplier of life-sustaining hemodialysis concentrates products to dialysis clinics. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
Company Info
Ticker SymbolRMTI
Company nameRockwell Medical Inc
IPO dateJan 27, 1998
CEODr. Mark Strobeck, Ph.D.
Number of employees244
Security typeOrdinary Share
Fiscal year-endJan 27
Address30142 Wixom Road
CityWIXOM
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code48393
Phone18004493353
Websitehttps://www.rockwellmed.com/
Ticker SymbolRMTI
IPO dateJan 27, 1998
CEODr. Mark Strobeck, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Mark Strobeck, Ph.D.
Dr. Mark Strobeck, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.62K
-2.33%
Mr. Mark H. Ravich
Mr. Mark H. Ravich
Independent Director
Independent Director
151.10K
+49.45%
Mr. John G. Cooper, CPA
Mr. John G. Cooper, CPA
Independent Director
Independent Director
145.45K
+52.38%
Ms. Megan Timmins, J.D.
Ms. Megan Timmins, J.D.
Executive Vice President, Chief Legal Officer, Secretary
Executive Vice President, Chief Legal Officer, Secretary
142.68K
+215.79%
Ms. Andrea Heslin Smiley
Ms. Andrea Heslin Smiley
Independent Director
Independent Director
142.06K
+54.31%
Mr. Timothy Chole
Mr. Timothy Chole
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
130.99K
-2.14%
Dr. Joan Lau, Ph.D.
Dr. Joan Lau, Ph.D.
Independent Director
Independent Director
113.11K
+79.23%
Mr. Jesse Neri
Mr. Jesse Neri
Chief Financial Officer, Senior Vice President - Finance
Chief Financial Officer, Senior Vice President - Finance
106.84K
-0.82%
Mr. Robert S. Radie
Mr. Robert S. Radie
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Heather R. Hunter
Ms. Heather R. Hunter
Senior Vice President, Chief Corporate Affairs Officer
Senior Vice President, Chief Corporate Affairs Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Mark Strobeck, Ph.D.
Dr. Mark Strobeck, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.62K
-2.33%
Mr. Mark H. Ravich
Mr. Mark H. Ravich
Independent Director
Independent Director
151.10K
+49.45%
Mr. John G. Cooper, CPA
Mr. John G. Cooper, CPA
Independent Director
Independent Director
145.45K
+52.38%
Ms. Megan Timmins, J.D.
Ms. Megan Timmins, J.D.
Executive Vice President, Chief Legal Officer, Secretary
Executive Vice President, Chief Legal Officer, Secretary
142.68K
+215.79%
Ms. Andrea Heslin Smiley
Ms. Andrea Heslin Smiley
Independent Director
Independent Director
142.06K
+54.31%
Mr. Timothy Chole
Mr. Timothy Chole
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
130.99K
-2.14%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Concentrate Products
18.59M
98.28%
Drug Products
325.00K
1.72%
By RegionUSD
Name
Revenue
Proportion
United States
16.44M
86.90%
Rest of World
2.48M
13.10%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Concentrate Products
18.59M
98.28%
Drug Products
325.00K
1.72%
Shareholding Stats
Updated: Sun, May 25
Updated: Sun, May 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Irrevocable Larson Family Investment Trust
10.41%
Armistice Capital LLC
6.92%
The Vanguard Group, Inc.
3.53%
GlobeFlex Capital, L.P.
2.17%
Renaissance Technologies LLC
1.33%
Other
75.64%
Shareholders
Shareholders
Proportion
Irrevocable Larson Family Investment Trust
10.41%
Armistice Capital LLC
6.92%
The Vanguard Group, Inc.
3.53%
GlobeFlex Capital, L.P.
2.17%
Renaissance Technologies LLC
1.33%
Other
75.64%
Shareholder Types
Shareholders
Proportion
Corporation
10.41%
Hedge Fund
8.67%
Investment Advisor
7.72%
Individual Investor
4.42%
Investment Advisor/Hedge Fund
3.56%
Research Firm
0.77%
Pension Fund
0.05%
Other
64.41%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
115
12.12M
35.46%
-1.47M
2025Q1
124
11.25M
32.97%
-1.96M
2024Q4
123
12.47M
38.59%
-1.21M
2024Q3
113
13.08M
41.13%
+2.79M
2024Q2
102
9.50M
31.23%
+460.06K
2024Q1
118
5.89M
19.90%
-1.12M
2023Q4
118
5.97M
23.48%
-688.25K
2023Q3
122
6.04M
24.13%
+2.56M
2023Q2
133
3.92M
24.44%
+947.21K
2023Q1
150
2.67M
21.21%
-974.16K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Irrevocable Larson Family Investment Trust
3.56M
10.41%
+87.50K
+2.52%
Apr 11, 2025
Armistice Capital LLC
2.37M
6.92%
-677.53K
-22.26%
Mar 31, 2025
The Vanguard Group, Inc.
1.21M
3.53%
+1.50K
+0.12%
Mar 31, 2025
GlobeFlex Capital, L.P.
743.26K
2.17%
--
--
Mar 31, 2025
Renaissance Technologies LLC
453.00K
1.33%
+10.65K
+2.41%
Mar 31, 2025
Marshall Wace LLP
333.60K
0.98%
-262.76K
-44.06%
Mar 31, 2025
Geode Capital Management, L.L.C.
324.54K
0.95%
+4.12K
+1.29%
Mar 31, 2025
Strobeck (Mark)
297.55K
0.87%
+220.00K
+283.70%
May 20, 2025
BlackRock Institutional Trust Company, N.A.
215.67K
0.63%
-4.13K
-1.88%
Mar 31, 2025
Morgan Stanley & Co. LLC
164.10K
0.48%
+69.13K
+72.79%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Dimensional US Core Equity 1 ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 12, 2022
Merger
11<1
May 12, 2022
Merger
11<1
May 12, 2022
Merger
11<1
May 12, 2022
Merger
11<1
Date
Type
Ratio
May 12, 2022
Merger
11<1
May 12, 2022
Merger
11<1
May 12, 2022
Merger
11<1
May 12, 2022
Merger
11<1
